Complement System(补体系统)
The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. The complement system consists of a number of small proteins found in the blood, in general synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex. Over 30 proteins and protein fragments make up the complement system. Three biochemical pathways activate the complement system: the classical complement pathway, the alternative complement pathway, and the lectin pathway.
Products for Complement System
- Cat.No. 产品名称 Information
-
GC70017
Tesidolumab
LFG316; Anti-Human C5 Recombinant Antibody
Tesidolumab (LFG316) 是一种全人IgG1/Λ抗c5单克隆抗体,分子量为143 kDa(不含糖基化)。Tesidolumab (LFG316)阻断C5的切割,防止膜攻击复合体的后续形成。 -
GC61335
TLQP-21 TFA
TLQP-21TFA是VGF衍生的具有内分泌和内分泌特性的肽,是一种强效的G蛋白偶联受体补体3a受体1(C3aR1)激动剂(EC50:小鼠TLQP-21=10.3μM;人TLQP-21=68.8μM)。TLQP-21TFA激活C3aR1,从而诱导细胞内Ca2+的增加。TLQP-21TFA可用于研究调节伤害感受和其他相关生理功能。
-
GC63858
Vemircopan
ALXN2050; ACH 0145228; ACH-5228
Vemircopan (ALXN2050) 是一种具有口服活性的补体因子 D (FD) 抑制剂。 -
GC70116
Vesencumab
MNRP-1685A
Vesencumab (MNRP-1685A) 是针对 neuropilin-1 (NRP-1) 的 IG1 抗体。Vesencumab 与 NRP-1 结合并阻止 NRP-1 与 VEGFR-2 偶联。Vesencumab 具有抗血管生成和抗肿瘤活性。Vesencumab可用于转移性实体瘤的研究,包括卵巢癌。 -
GC17129
W 54011
A selective C5aR antagonist
-
GC70170
Zilucoplan
RA101495
Zilucoplan (RA101495) 是一种 15 个氨基酸的大环肽,是一种有效的补体成分 5 (C5) 抑制剂。Zilucoplan 可用于免疫介导的坏死性肌病 (IMNM) 研究。 -
GC74045
Zoracopan
Zoracopan是一种选择性补体因子D(CFD)抑制剂。